Primate Studies to Evaluate TGF-Alpha for Parkinson's

By Biotechdaily staff writers
Posted on 30 Sep 2002

Primate studies to evaluate the potential of transforming growth factor alpha (TGF-alpha) to treat Parkinson's disease are being conduced by researchers at the Surgical Neurology Branch of the US National Institutes of Health (Bethesda, MD, USA).

The studies are focused on analyzing the proliferative effect of TGF-alpha on brain stem cells in those critical regions of the brain affected by Parkinson's disease, as well as defining drug delivery parameters in anticipation of human trials. More...

TGF-alpha will be delivered to the primates using convection-enhanced drug delivery (CED), designed to ensure optimal delivery of the drug to bodily tissues, including the brain.

"Preliminary studies in animal models have shown substantial promise for TGF-alpha for the treatment of Parkinson's disease,” said Dr. Edward Oldfield, chief of the Surgical Neurology Branch and leader of the study. CED delivery was developed in Dr. Oldfield's laboratory.

The study will use a proprietary compound of TGF-alpha produced by Kaleidos Pharma, Inc. (Seattle, WA, USA), under a special agreement with the company. TGF-alpha was originally discovered by Dr. George Todaro, of the US National Academy of Sciences, and Dr. Daniel Twardzik, vice president, research, at Kaleidos Pharma. Studies have shown that TFG-alpha causes replacement of lost nerve cells and reverses symptoms in an established animal model of Parkinson's disease.

Related Links:
National Institutes of Health

Visit expo >

Platinum Member

Xylazine Immunoassay Test

Xylazine ELISA

Verification Panels for Assay Development & QC
Seroconversion Panels

Anti-Cyclic Citrullinated Peptide Test

GPP-100 Anti-CCP Kit

Gold Member

COVID-19 Antigen Self-Test

Panbio COVID-19 Antigen Self-Test

Read the full article by registering today, it's FREE!

Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.

Free digital version edition of LabMedica International sent by email on regular basis
Free print version of LabMedica International magazine (available only outside USA and Canada).
Free and unlimited access to back issues of LabMedica International in digital format
Free LabMedica International Newsletter sent every week containing the latest news
Free breaking news sent via email
Free access to Events Calendar
Free access to LinkXpress new product services
REGISTRATION IS FREE AND EASY!